| References: |
NLG-8189 is an inhibitor of the enzymes and indolamine 2,3-dioxygenase 1 (IDO) and indolamine 2,3-dioxygenase 2 (INDOL1), with selectivity for INDOL1. The enzymes perform similar transformations and are responsible for catalyzing the rate-limiting step of oxidative tryptophan catabolism in the kynurenine pathway. IDO activity is correlated with an induction of tolerance and immunosuppresion through activation of regulatory T cells by metabolites generated from tryptophan catabolism. Inhibition of IDO by NLG-8189 blocks this induced immune suppression, which has shown utility in suppressing acquired immunities of tumors and indicates potential for chemical intervention of chronic inflammatory diseases.
For the detailed information of Indoximod (NLG-8189), the solubility of Indoximod (NLG-8189) in water, the solubility of Indoximod (NLG-8189) in DMSO, the solubility of Indoximod (NLG-8189) in PBS buffer, the animal experiment (test) of Indoximod (NLG-8189), the cell expriment (test) of Indoximod (NLG-8189), the in vivo, in vitro and clinical trial test of Indoximod (NLG-8189), the EC50, IC50,and affinity,of Indoximod (NLG-8189), Please contact DC Chemicals. |
